Log in or Sign up for Free to view tailored content for your specialty!
Neurocritical Care News
Antidopaminergics linked to worse cognitive, functional outcomes in HD at 6 years
Antidopaminergic medications were linked to worsening cognitive and functional effects that accelerate disease progression in Huntington’s disease, according to research presented at the Congress of the European Academy of Neurology.
FDA grants RMAT designation for stiff person syndrome therapy
The FDA has granted Regenerative Medicine Advanced Therapy designation to a Bay Area-based biopharmaceutical company for its autologous, fully human CD19 chimeric antigen receptor to treat those with refractory stiff person syndrome.
Log in or Sign up for Free to view tailored content for your specialty!
NYU Langone tops list again as best US hospital for neurology, neurosurgery
NYU Langone was again the top hospital in the United States for neurology and neurosurgery, according to the latest annual Best Hospitals Survey issued by U.S. News & World Report.
Initial testing promising for hemostatic hydrogel to treat TBI
A Brooklyn-based biotech firm has announced successful completion of the first phase of a preclinical study conducted with the Walter Reed Army Institute of Research involving a proprietary hemostatic hydrogel to treat traumatic brain injury.
Ketamine may be better option than ECT for less severe treatment-resistant depression
Individuals with moderate to less severe treatment-resistant depression may benefit from treatment with ketamine instead of electroconvulsive therapy, according to research from JAMA Network Open.
No significant difference in clinical outcomes, recovery in college athletes with concussion
No significant differences were found in clinical outcomes or recovery time in college athletes who returned to play following concussion compared with those immediately removed, according to research from Neurosurgical Focus.
Disease progression slowed by 80% at 24 months in phase 1/2 studies of HD gene therapy
Interim results of phase 1/2 clinical trials of an investigational gene therapy for Huntington’s disease showed that disease progression slowed by 80% at 24 months, according to the manufacturer.
Brain stimulation may have distinct near-maximal effective doses across mental disorders
Significant dose-response associations were found for transcranial magnetic stimulation and transcranial direct current stimulation across several mental disorders, including schizophrenia and depression, according to research.
Interim phase 1/2a study results positive for investigational Parkinson’s cell therapy
A South Korean biomedical company has announced positive 1-year assessment data from a phase 1/2a clinical trial of a human embryonic stem cell-derived midbrain dopaminergic progenitor for Parkinson’s disease.
Subcutaneous combination therapy improves ‘good on’ time in Parkinson’s
Treatment with an investigational subcutaneous combination therapy for Parkinson’s disease improved ‘good on’ time by almost 2 hours per day, was safe and efficacious with treatment effect similar across a range of subgroups.
-
Headline News
Study: Young patients hesitant to tell providers information their parents might see
November 06, 20242 min read -
Headline News
Q&A: Adults may know their risk for COPD with blood test
November 07, 20243 min read -
Headline News
CMS increases payment for dialysis facilities, includes oral-only drugs in the bundle
November 08, 20242 min read
-
Headline News
Study: Young patients hesitant to tell providers information their parents might see
November 06, 20242 min read -
Headline News
Q&A: Adults may know their risk for COPD with blood test
November 07, 20243 min read -
Headline News
CMS increases payment for dialysis facilities, includes oral-only drugs in the bundle
November 08, 20242 min read